Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
UK clothing inflation climbs as Middle East turmoil threatens wider price rises - 2Why ordering takeout or calling the dog walker might lead to a happier relationship
- 3Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- 4New dietary guidelines recommend more dairy, meat and fats: What to know
- 5Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Farmers worry about rising cost of fertiliser
- Germany's Pistorius: NATO protects Europe from Iranian missiles
- Volkswagen in talks with defence firms on use of Germany plant: CEO
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- IDF destroys regime's missile, sea mine production site in Yazd amid nationwide airstrikes
- Building a Flourishing Business: Illustrations from Business people
